Molecular biology as a tool for the treatment of cancer

被引:30
作者
de Castro Sant' Anna, Carla [1 ,2 ]
Ferreira Junior, Alberto Gomes [1 ]
Soares, Paulo [1 ]
Tuji, Fabricio [1 ]
Paschoal, Eric [1 ]
Chaves, Luiz Claudio [1 ]
Burbano, Rommel Rodriguez [1 ]
机构
[1] Ophir Loyola Hosp, Mol Biol Lab, Ave Governador Magalhaes Barata 992, BR-66063240 Belem, Para, Brazil
[2] Joao de Barros Barreto Univ Hosp, Belem, Para, Brazil
关键词
Biomarkers; Epigenetics; Molecular biology; Cancer; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; FAMILIAL GASTRIC-CANCER; TYROSINE KINASE INHIBITORS; MGMT PROMOTER METHYLATION; E-CADHERIN MUTATIONS; BCR-ABL TRANSCRIPTS; GERMLINE MUTATIONS; HELICOBACTER-PYLORI; IMATINIB-RESISTANT;
D O I
10.1007/s10238-018-0518-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancer is a genetic disease characterized by uncontrolled cell growth and metastasis. Cancer can have a number of causes, such the activation of oncogenes, the inactivation of tumor-suppressing genes, mutagenesis provoked by external factors, and epigenetic modifications. The development of diagnostic tools and treatments using a molecular biological approach permits the use of sensitive, low-cost, noninvasive tests for cancer patients. Biomarkers can be used to provide rapid, personalized oncology, in particular the molecular diagnosis of chronic myeloid leukemia, and gastric, colon, and breast cancers. Molecular tests based on DNA methylation can also be used to direct treatments or evaluate the toxic effects of chemotherapy. The adequate diagnosis, prognosis, and prediction of the response of cancer patients to treatment are essential to ensure the most effective therapy, reduce the damaging effects of treatment, and direct the therapy to specific targets, and in this context, molecular biology has become increasingly important in oncology. In this brief review, we will demonstrate the fundamental importance of molecular biology for the treatment of three types of cancerchronic myeloid leukemia, hereditary diffuse gastric cancer, and astrocytomas (sporadic tumors of the central nervous system). In each of these three models, distinct biological mechanisms are involved in the transformation of the cells, but in all cases, molecular biology is fundamental to the development of personalized analyses for each patient and each type of neoplasia, and to guarantee the success of the treatment.
引用
收藏
页码:457 / 464
页数:8
相关论文
共 118 条
  • [31] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
    Giles, Francis J.
    Cortes, Jorge
    Jones, Dan
    Bergstrom, Donald
    Kantarjian, Hagop
    Freedman, Steven J.
    [J]. BLOOD, 2007, 109 (02) : 500 - 502
  • [32] Golas JM, 2003, CANCER RES, V63, P375
  • [33] Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
    Goldman, JM
    Melo, JV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) : 1451 - 1464
  • [34] Chronic Myeloid Leukemia: A Historical Perspective
    Goldman, John M.
    [J]. SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 302 - 311
  • [35] Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
    Grady, WM
    Willis, J
    Guilford, PJ
    Dunbier, AK
    Toro, TT
    Lynch, H
    Wiesner, G
    Ferguson, K
    Eng, C
    Park, JG
    Kim, SJ
    Markowitz, S
    [J]. NATURE GENETICS, 2000, 26 (01) : 16 - 17
  • [36] Intercellular Junction Assembly, Dynamics, and Homeostasis
    Green, Kathleen J.
    Getsios, Spiro
    Troyanovsky, Sergey
    Godsel, L. M.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (02): : a000125
  • [37] A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
    Grossmann, V.
    Kohlmann, A.
    Zenger, M.
    Schindela, S.
    Eder, C.
    Weissmann, S.
    Schnittger, S.
    Kern, W.
    Mueller, M. C.
    Hochhaus, A.
    Haferlach, T.
    Haferlach, C.
    [J]. LEUKEMIA, 2011, 25 (03) : 557 - 560
  • [38] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Gruber, F. X.
    Ernst, T.
    Porkka, K.
    Engh, R. A.
    Mikkola, I.
    Maier, J.
    Lange, T.
    Hochhaus, A.
    [J]. LEUKEMIA, 2012, 26 (01) : 172 - 177
  • [39] E-cadherin germline mutations in familial gastric cancer
    Guilford, P
    Hopkins, J
    Harraway, J
    McLeod, M
    McLeod, N
    Harawira, P
    Taite, H
    Scoular, R
    Miller, A
    Reeve, AE
    [J]. NATURE, 1998, 392 (6674) : 402 - 405
  • [40] Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice
    Guilford, Parry
    Humar, Bostjan
    Blair, Vanessa
    [J]. GASTRIC CANCER, 2010, 13 (01) : 1 - 10